September 14, 2023 01:55 PM EDT
Pharma
Law

Alex­ion looks to set­tle law­suit over Soliris sales prac­tices for $125M

Katherine Lewin

News Reporter

A 2016 class ac­tion law­suit filed against Alex­ion claim­ing shady sales prac­tices caused a de­cline in stock price could be near­ing its end af­ter both …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Bio­gen of­fers to buy out strug­gling neu­ro part­ner Sage Ther­a­peu­tics

Post-Hoc: Big Phar­ma is los­ing the AI tal­ent war

Chas­ing the next wave of obe­si­ty drugs, Met­sera files for an IPO

Four biotechs emerge with $800M and in-li­censed as­sets on Fri­day

Ex­clu­sive: Mod­er­na's for­mer top sci­en­tist has a new start­up us­ing AI to im­prove mR­NA ther­a­pies

Lil­ly fi­nances new $500M biotech fund man­aged by a16z

A service from the Financial Times